Similar Items: Real-world clinical decision of andexanet alfa administration for intracranial hemorrhage during anticoagulant therapy using factor Xa inhibitor
- High Patient Willingness to Grant Broad Consent for Real-World Data Use in Rheumatology—Implications for Real-World Data Platform Governance: Cross-Sectional Study
- Real-world screening for interstitial lung disease in rheumatoid arthritis: the value of spirometry, DLCO, and clinical risk factors
- Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay
- Factor eight inhibitor bypassing activity for refractory bleeding in coronary artery bypass grafting: A propensity‐matched analysis
- In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan
- Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection